Johnson & Johnson has reported sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%. Net earnings per share for the second quarter of 2009 were $3.2 billion.
Worldwide Pharmaceutical sales of $5.5 billion for the second quarter represented a decrease versus the prior year of 13.3%, with an operational decline of 8.5% and a negative impact from currency of 4.8%.
Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the second quarter represented a decrease of 3.1% versus the prior year, with an operational increase of 2.9% and a negative currency impact of 6.0%.
William Weldon, chairman and chief executive officer of Johnson & Johnson, said: “I am proud of the accomplishments of our people in continuing to deliver very solid operational results in light of the significant impacts of patent expirations and the economic environment.
“Our investments through internal research and development, strategic partnerships and acquisitions have allowed us to build what is considered by many to be one of the best pipelines in our industry. We will continue to invest in our portfolio of innovative products to meet the needs of patients and consumers around the world,” he added.